Module 2: EWING family
Available from November 2026
Module 2: EWING family
Available from November 2026
02/11/2026
Ewing sarcoma epidemiology and presentation
02/11/2026
Biology of Ewing sarcoma
02/11/2026
Localised Ewing sarcoma first line : treatments evolution and new drug development
02/11/2026
Surgery as local treatment of the primary tumor
02/11/2026
Role of radiotherapy in Ewing sarcoma
02/11/2026
Role of multidisciplinary tumour board
02/11/2026
Metastatic Ewing sarcoma: first line treatment - (live lecture)
02/11/2026
Local treatment of metastases
02/11/2026
Maintenance therapy in Ewing sarcomas
02/11/2026
Ewing sarcoma expert network
02/11/2026
Ewing sarcoma at relapse: how to change evolution?
02/11/2026
Shall we treat bone ressebling Ewing sarcome the same (BCOR-CCNB3, CIC-DUX4)
02/11/2026
The strength of collaborative consortia
02/11/2026
Role of patient and parents to improve Ewing sarcoma
02/11/2026
Clinical case discussion (live online session)
Module director: Gaspar Nathalie, FR
Antonio Juan Ribelles
Hospital Universitari i Politecnic La Fe, Pediatric Oncology, Valencia, ES
Beate Timmermann
UK-Essen, WPE, Essen, DE
Emanuela Palmerini
IOR - Istituto Ortopedico Rizzoli, Oncology Dpt., Bologna, IT
Imogen Westwood
UK
Lianne Haveman
Academic Medical Center Amsterdam, Paediatric Oncology Dpt., Amsterdam, NL
Martin McCabe
Royal Marsden Hospital, Pediatric Dpt., Cambridge, UK
Mehdi Brahmi
Centre Leon Berard, Sarcoma Dpt., Lyon, FR
Michiel Van De Sande
., ., ., NL
Nathalie Gaspar
Gustave-Roussy Institute, Oncology Dpt., Villejuif, FR
Pablo Berlanga
Gustave Roussy, Dept. of Pediatric and Adolescent Oncology, Villejuif, FR
Salvatore Provenzano
Segrate, IT
Sandra Strauss
UCL Cancer Institute, Medical Oncology Dept., London, UK
Waisse Waissi
Unicancer, Lyon, FR
